Skip to content

Clinical trials

Neurotoxicity Syndromes trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neurotoxicity Syndromes Phase: Not applicable Clear all

21 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20051
20061
20071
20102
20131
20141
20172
20202
20211
20222
20231
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed9
Recruiting4
Unknown status3
Terminated2
Withdrawn2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assaf-Harofeh Medical Center1
Beth Israel Deaconess Medical Center1
Case Comprehensive Cancer Center1
City of Hope Medical Center1
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico1
Fudan University1
Hong Kong Baptist University1
Instituto de Investigacion Sanitaria INCLIVA1
Ka-Wai Ho1
Massachusetts General Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neurotoxicity Syndromes21
Breast Neoplasms3
Peripheral Nervous System Diseases3
Gastrointestinal Neoplasms2
Hematologic Neoplasms2
Amphetamine-Related Disorders1
Brain Damage, Chronic1
Brain Diseases1
Brain Diseases, Metabolic1
Breast Neoplasms, Male1

Trials

Showing 26 to 21 of 21. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.